CD274 and non-small cell lung carcinoma: PD-L1 TPS is, to a certain degree, associated with the response rate; unselected patients with NSCLC in the KEYNOTE-001 trial showed a response rate of 19.4% [9], while patients with NSCLC with a PD-L1 TPS of at least 50% in the KEYNOTE-024 trial had a response rate of 44.8% [6].